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Abstract
Background: Co-administration of dextromethorphan (DM) with morphine during pregnancy and throughout
lactation has been found to reduce morphine physical dependence and tolerance in rat offspring. No evidence
was presented, however, for the effect of DM co-administered with morphine during pregnancy on inflammatory
hyperalgesia in morphine-exposed offspring. Therefore, we attempt to investigate the possible effect of prenatal
morphine exposure on the vulnerability to hyperalgesia and the possible therapeutic effect of DM in the present
study.
Methods: Fifty μl of carrageenan (20 mg/ml) was injected subcutaneously into the plantar surface of the right
hind paw in p18 rats to induce hyperalgesia. Mean paw withdrawal latency was measured in the plantar test to
index the severity of hyperalgesia. Using Western blotting and RT-PCR, the quantitative analyses of NMDA receptor
NR1 and NR2B subunits were performed in spinal cords from different groups of animals.
Results: In the carrageenan-induced hyperalgesia model, rat offspring passively exposed to morphine developed a
severe hyperalgesia on postnatal day 18 (p18), which also had a more rapid time course than those in the controls.
Co-administration of DM with morphine in the dams prevented this adverse effect of morphine in the offspring
rats. Western blot and RT-PCR analysis showed that the levels of protein and mRNA of NMDA receptor NR1 and
NR2B subunits were significantly higher in the lumbar spinal cords of rats (p14) exposed to prenatal morphine; the
co-administration of DM could reverse the effect of morphine on NR1 and attenuate the effect on NR2B.
Conclusions: Thus, DM may have a great potential in the prevention of higher vulnerability to inflammatory
thermal hyperalgesia in the offspring of morphine-addicted mothers.
Background
Growth retardation, delayed motor development and
behavior abnormalities have been proposed in offspring
of heroin-addicted mothers [1]. Infants passively exposed
to morphine through their addicted mothers easily devel-
oped morphine withdrawal syndrome after birth, and
even needed intensive care [2-4]. In our previous studies,
we observed that many adverse effects caused by prenatal
exposure of morphine could be prevented by the co-
administration of dextromethorphan (DM) in morphine-
dependent rat dams [5,6]. However, the possible impacts
of prenatal exposure of morphine on the vulnerability to
hyperalgesia have never been examined. In humans, the
liability to inflammatory hyperalgesia is often affected by
acquired physical conditions and social factors in off-
spring from morphine-addicted mother [7]. Thus, we
attempted to investigate the possible effects of prenatal
exposure to morphine on the vulnerability to hyperalge-
sia in a rat model. In addition, the possible protective
effect of the co-administered DM was also tested.
Being a non-competitive antagonist at the glutamater-
gic NMDA receptors, DM is thought to exert many of
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NMDA receptor [8], although DM was reported to act
at the other targets (e.g. nicotinic a3b4 receptors and
sigma receptors) as well [9,10]. Activation of the NMDA
receptors has been implicated in the development of
inflammatory hyperalgesia and the regulation of reward-
ing-related mesolimbic pathway in many reports
[11-13]. Therefore, we speculated that the prenatal
administration of morphine and DM to the dams may
affect the development of the neural systems which will
be functionally correlated with hyperalgesia in the off-
spring. In order to investigate the vulnerability to hyper-
algesia, we used a plantar test in rats with intraplantar
carrageenan-induced inflammatory hyperalgesia to per-
form quantitative verification. These behavioral experi-
ments were carried out on the rats which were the
offspring from the morphine-dependent dams.
In the present study, we first demonstrated that the
prenatal exposure of morphine could increase the vul-
nerability to inflammatory hyperalgesia in the offspring.
Our biochemical results showed a clear increase of the
NR1 and NR2B subunits of NMDA receptors in the
spinal cord from the offspring (18 days old; p18) of
morphine-treated mother. This could provide some
neural developmental evidence which may be related to
the higher vulnerability to inflammatory hyperalgesia.
This adverse effect of prenatal morphine exposure could
be prevented by the co-administration of DM in the
dams. Overall, our results highlighted the possible
adverse effect of prenatal morphine exposure that is sel-
dom noticed. DM may also have a great therapeutic
potential in the prevention of the adverse effect.
Materials and methods
Animals
Adult female Sprague-Dawley rats were purchased from
the National Experimental Animal Centre, Taipei, Taiwan.
The animals were housed one or two in a cage, in a room
maintained at a temperature of 23 ±2°C with a 12 h light-
dark cycle. Food and water were available ad libitum
throughout the experiment. Rats were randomly separated
into four groups. Rats received subcutaneous (s.c.) injec-
tion of saline (Control group), morphine (M group), mor-
phine + dextromethorphan (M + DM group) and
dextromethorphan (DM group) twice per day (9 AM and
5 PM) and progressively increased with 1 mg/kg at 7-day
intervals from a beginning dose of 2 mg/kg for both mor-
phine and dextromethorphan. The rats were mated on day
8 and the drug administration was continued during preg-
nancy. After rat offspring were born, the dams were
housed separately in individual cages and the injections of
drugs into the dams were stopped. Four groups of neona-
tal rats of either sex aged 18 days (p18) were used for the
plantar test. P14 rats were used for Western blot and RT-
PCR analysis. The care of animals was carried out in
accordance with institutional and international standards
(Principles of Laboratory Animal Care, National Institutes
of Health), and the protocol was approved by the Institu-
tional Animal Care and Use Committee of National
Defense Medical Center, Taiwan, R.O.C.
Determination of carrageenan-induced thermal
hyperalgesia
P18 rats from four groups were used for plantar tests.
Fifty μl of carrageenan (20 mg/ml) was injected subcuta-
neously via a 28-G needle into the plantar surface of the
right hind paw. A plantar analgesiometer (7370, Ugo
Basile, Italy) was used to index thermal hyperalgesia
[14]. Mean paw withdrawal latency in response to the
stimulus from a focused beam of I.R. light served as the
measure of thermal nociception. Cut-off time of the paw
withdrawal latency was set at 10 sec to prevent thermal
injury. Animals were all injected with carrageenan on
the right hind paw that was subjected to the determina-
tion of paw withdrawal latency. The paw withdrawal
latencies were measured before carrageenan injection (0
hour), and at the time points after carrageenan injection:
3, 6, 9, 12, 24, 48 hours. The paw withdrawal latency of
each rat was tested for three times at each time point.
Two closer values of latencies were selected and aver-
aged as the final data to be used. The paw withdrawal
latencies were calculated and converted to the percen-
tage of the basal latency for comparison.
Western blot analysis
P14 rats from four groups were sacrificed by decapita-
tion, and their lumbar (L1 to L6) spinal cords were
quickly dissected. These tissues were immediately frozen
in liquid nitrogen and kept at -80°C until use. The tis-
sues were disrupted by homogenization on ice in lysis
buffer [Tris-HCl 0.05 M, EDTA 5 mM, NaCl 0.15 M,
Triton X-100 1%, aprotinin 0.5 μg/ml, leupeptin 0.5 μg/
ml, phenylmethanesulfonyl fluoride (PMSF) 30 μg/ml,
1,4-dithiothreitol (DTT) 5 mM]. Tissue lysates were
obtained by first centrifugation at 1,000 × g for 10 min,
followed by the second centrifugation of the previous
supernatant at 35,000 × g for 30 min at 4°C. Protein
concentrations were estimated by the BCA protein assay
(Pierce, U.S.A.) using bovine serum albumin (BSA) as
standards. For Western blot analysis, 25 μgp r o t e i no f
the lysates was dissolved in sample buffer (Tris 0.2 M,
SDS 0.8%, glycerol 5%, DTT 3.1 mg/ml, bromophenol
blue 0.04 mg/ml), boiled for 5 min, and subjected to
SDS-PAGE (10% polyacrylamide). The proteins on the
gel were transferred to a polyvinylidene fluoride (PVDF)
membrane (FluoroTrans W membrane, pore size: 0.2
μm, PALL Life Sciences, U.S.A.) using a GENIE electro-
phoretic transfer apparatus (Idea Scientific, U.S.A.). The
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anti-NMDA NR1 monoclonal antibody, anti-NMDA
NR2B polyclonal antibody (Novus Biologicals, U.S.A.),
and anti-b-actin monoclonal antibody (Sigma, U.S.A.)]
at 4°C over night, and then incubated with secondary
antibody [1:2K; anti-rabbit IgG HRP conjugated anti-
body and anti-mouse IgG HRP conjugated antibody
(Alpha Diagnostic, U.S.A.)] for one hour. The bands of
proteins were revealed by ECL Western blotting detec-
tion kit (Amersham Biosciences, U.K.) and visualized on
an X-ray film. Using Kodak Digital Science 1D image
analysis software, the optical density of each band was
analyzed. The value was calculated as the ratio of the
density of corresponding b-actin bands. These ratios
were then normalized with the mean ratio obtained
from the control group, which was set as 100%.
Reverse transcription polymerase chain reaction (RT-PCR)
Tissue samples were obtained from the lumbar spinal
cords of the p14 rats from four groups. These P14 rats
were sacrificed by decapitation, and their lumbar (L1 to
L6) spinal cords were quickly dissected. These tissues
were immediately frozen in liquid nitrogen and kept at
-80°C. Total RNA of the samples was extracted with EZ-
10 Spin Column Total RNA MiniPreps Super Kit (Bio
Basic Inc., Canada). One μg of total RNA was used per
PCR condition. Using the One-Step RT PCR kit (Gene-
Mark, Taiwan, R.O.C.), forty PCR cycles were performed
and the products were subjected to agarose gel electro-
phoresis. Primers used were (5’-3’, sense/antisense):
TGGGACACGGCTCTGGAAG/TAGGCGGGTGGC-
TAACTA for NR1, AGCCAAGAGGAGGAAACAGC/
ACCTCCACTGACCGAATCTC for NR2B). Using
Kodak Digital Science 1D image analysis software, quan-
titative analysis was performed after scanning of the ethi-
dium bromide-stained agarose gel pictures. The method
of quantification was similar to that used in Western
blotting, but the bands of GAPDH were used as the
internal controls.
Statistical analysis
The data were all expressed as means ± SEM. One-way
ANOVA followed by Newman-Keuls test was employed
to examine the statistical significance of the difference
between groups.
Results
Chronic morphine administration of the dams caused a
higher sensitivity to noxious stimuli and more severe
inflammatory hyperalgesia in the offspring rats (p18),
which could be prevented by the co-administration of
DM in the dams
Before carrageenan injection, p18 rats of the morphine
group showed a significantly shorter paw withdrawal
latency, when compared with that of the control group
(7.2 ± 0.2 sec versus 8.4 ± 0.4 sec, n = 8, p < 0.001) (Fig-
ure 1A). P18 rats of the M + DM group showed a simi-
lar paw withdrawal latency (8.1 ± 0.4 sec, n = 7) to that
of the control group. There was no significant difference
of the paw withdrawal latency between the DM group
(8.1 ± 0.4 sec, n = 10) and the control group. These
data suggest that chronic morphine administration of
the dams caused a higher sensitivity to noxious stimuli
in the offspring rats. This effect of morphine could be
prevented by the co-administration of DM, whereas DM
alone did not cause any significant change in the sensi-
tivity to noxious stimuli.
To examine the effect on inflammatory hyperalgesia,
paw withdrawal latency was determined on hour 3, 6, 9,
12, 24, 48 after carrageenan injection (Figure 1B). In the
control group, the paw withdrawal latency was signifi-
cantly decreased to 44.5 ± 2.7% and 31.2 ± 2.8% of the
basal value (value on hour 0) on hour 3 and hour 6,
respectively. This indicates a clear thermal hyperalgesia
induced by intra-plantar carrageenan injection in our
model. In the morphine group, the paw withdrawal
latency was significantly decreased to 33.8 ± 2.4% and
24.1 ± 1.4% of the basal value on hour 3 and hour 6,
respectively. These latencies decreased to a lower level
in comparison with those of the control group (p <
0.001) (Figure 1B). There was no significant difference
between the M + DM group and the control group.
These results indicate that the offspring rats from the
m o r p h i n eg r o u ps h o w e dam o re severe inflammatory
hyperalgesia, which developed more rapidly compared
to controls. However, co-administration of DM with
morphine in the dams effectively prevented this adverse
effect in the offspring rats. But DM alone did not induce
any effect on hyperalgesia.
The quantitative change of NR1/NR2B mRNA and protein
expression in the offspring rats from morphine/DM/
(morphine + DM)-treated dams
In the experiments of Western blots, we found that
there was an increase of the expression of NR1 and
NR2B subunits of the NMDA receptor within the spinal
cord from p14 rats of the morphine group (Figure 2A;
2C). When the quantities of the expression of NR1 and
NR2B subunits in the control group were set as 100%,
the respective values from the morphine group were
121.1 ± 1% in NR1 subunit (p < 0.05) and 155 ± 6.9% in
NR2B subunit (p < 0.001) (Figure 2B; 2D). In the M +
DM group, there was no significant difference from that
of the control group in NR1 subunit (96.5 ± 27%), but a
significant increase of the NR2B subunit (122.3 ± 7.5%,
p < 0.05) was still observed. Compared with the mor-
phine group, there was a significant lower level of NR2B
subunit in the M + DM group (p < 0.05) (Figure 2D).
Tao et al. Journal of Biomedical Science 2011, 18:64
http://www.jbiomedsci.com/content/18/1/64
Page 3 of 7Control M M+DM DM
0.0
2.5
5.0
7.5
10.0
**
P
a
w
 
w
i
t
h
d
r
a
w
a
l
 
l
a
t
e
n
c
y
 
(
s
e
c
)
0 3 6 9 12 15
20
30
40
50
60
70
80
90
100
Time (hour)
**
**
21 24 2747 49
%
 
o
f
 
b
a
s
a
l
 
p
a
w
 
w
i
t
h
d
r
a
w
a
l
 
l
a
t
e
n
c
y
AB
Figure 1 (A) The paw withdrawal latency was obtained by plantar tests before carrageenan injection in the offspring rats (P18) of
different groups.( B) The time-course of the hyperalgesia effect induced by carrageenan injection (50 μl, 20 mg/ml). In (B), the different marks
and lines represent the results from different groups (filled circle: Control, open circle: M, open square: M + DM, filled square: DM). Data are
presented as mean ± SEM. One-way ANOVA followed by the Newman-Keuls test was used to analyze the data. (A:* * p < 0.001 for the morphine
group vs the control group; B:* * p < 0.001, for the morphine group vs the control group) (Control group: n = 8; M group: n = 8; M + DM group:
n = 7; DM group: n = 10).
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Figure 2 (A), (C): The blots show the examples of immunobands against NR1 (A)a n dN R 2 B( C)a n db-actin antibodies on the
membrane, which was performed on the membrane protein prepared from the lumbar spinal cords of the offspring (P14) rats in
different groups.( B), (D): The quantitative change of NR1 (B) and NR2B (D) protein expression. The values of NR1 and NR2B subunits in the
control group were arbitrarily set at 100%. Data are presented as mean ± SEM. One-way ANOVA followed by the Newman-Keuls test was used
to analyze the data. (B:* p < 0.05 for the morphine group vs the control group; D:* * p < 0.001 for the morphine group vs the control group; *p
< 0.05 for the M + DM group vs the control group; ¶p < 0.01 for the M + DM group vs the morphine group, n = 3).
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of mRNA of NR1 and NR2B subunits were also
increased in the spinal cords from p14 rats of the mor-
phine group (Figure 3A; 3C). When the mRNA values
of NR1 and NR2B subunits in the control group were
set as 100%, the respective values from the morphine
group were significantly increased to 149.3 ± 16% in
NR1 subunit (p < 0.01) and to 132 ± 7% in NR2B subu-
nit (p < 0.01) (Figure 3B; 3D). In the M + DM group,
there was no significant difference from that of the con-
trol group in both NR1 (96.6 ± 1.4%) and NR2B subu-
nits (93.6 ± 6.4%) (Figure 3B; 3D).
Discussion
Previously, we found that the co-administration of dex-
tromethorphan with morphine to dam rats throughout
pregnancy significantly decreased morphine physical
dependence and tolerance in their offspring [5]. In the
present study, our results suggested that co-administra-
tion of DM with morphine during pregnancy could
possibly attenuate the vulnerability to inflammatory
hyperalgesia in offspring rats from the dam with chronic
morphine exposure. In our experiments, we first
observed a lower thermal pain threshold in the offspring
rats from morphine-addicted mother. But the pain
threshold was found to be as same as that of the control
group, when DM was co-administered with morphine in
the dams. This implied a higher sensitivity to pain was
induced by prenatal exposure to morphine in the dams,
which could be diminished by the co-administration of
DM. Hovious and Peters first demonstrated that chronic
maternal exposure to morphine has a significant effect
on the effectiveness of analgesic drugs in the offspring
rats [15]. Their results showed decreased response laten-
cies in offspring (p25 and p120) from morphine-treated
mother in both tail-flick and hot-plate tests. Although it
was more significant in female offspring rats, this report
suggested that chronic maternal exposure of morphine
could possibly increase the sensitivity to pain in the off-
spring rats. The following studies also confirmed this
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Figure 3 (A), (C): An example of RT-PCR results for the levels of mRNA of NMDA receptor NR1 (A) and NR2B (C) subunits and GAPDH.
(B), (D): The quantitative RT-PCR results for the levels of mRNA of NMDA receptor NR1 (B) and NR2B (D) subunit of the offspring rats (P14) in
different groups. In (A), each white letter at the bottom of the lane represents the result from certain group (a: Control, b: M, c: M + DM, d: DM).
The values of NR1 and NR2B subunits in the control group were arbitrarily set at 100%. Data are presented as mean ± SEM. One-way ANOVA
followed by the Newman-Keuls test was used to analyze the data. (B:* * p<0.01 for the morphine group vs the control group; D:* * p < 0.01, for
the morphine group vs the control group, n = 3).
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Page 5 of 7finding of morphine’s prenatal effects [16,17]. Although
the dosage and schedule of the maternal morphine
administration are different, our current results are con-
sistent with these reports. Moreover, we found that
maternal co-administration of DM with morphine could
prevent the increase of pain sensitivity in the offspring.
In the present study, we further examined the possible
effect of morphine’s prenatal effect on inflammatory
hyperalgesia. Using carrageenan-induced plantar inflam-
mation and plantar test, we observed a more severe
hyperalgesia in offspring from morphine-treated dams.
Again, this effect could be prevented by the maternal
co-administration of DM with morphine. Since maternal
treatment of DM itself did not cause any effect on the
antinociceptive response and hyperalgesia, DM may be
of great therapeutic potential in correlation with the les-
sening of adverse effects in offspring from morphine-
addicted female patients. In view of the age of offspring
rats to be tested, we used p18 rats of either sex in the
plantar tests. This is also the age of rats showing most
significant difference in nociceptive sensitivity between
control and prenatal morphine-treated group, which was
reported by Zhang and Sweitzer [17]. In this recent
report, they found that there was no difference of noci-
ceptive sensitivity between groups at the age over p50.
In search of the possible underlying mechanisms, we
examined the level of protein and mRNA of NMDA
receptor NR1 and NR2B subunits in the lumbar spinal
cords of offspring rats (p14) from different groups. The
data showed that the level of NMDA receptor NR1 and
NR2B subunits were significantly higher in the mor-
phine group, whereas the maternal co-administration of
D Mc o u l dr e v e r s et h ee f f e c to nN R 1b u ta t t e n u a t et h e
effect on NR2B. Moreover, the prenatal exposure of DM
alone did not change the expression of NR1 and NR2B.
Interestingly, the mRNA data for NR2B seem to show
that the maternal co-administration of DM could totally
reverse the effect caused by morphine, which is different
from the decrease of NR2B at the protein level. This
may be due to the low sensitivity of RT-PCR quantifica-
tion or the difference between the level of mRNA and
protein. The correlation between the NMDA-receptor
system and hyperalgesia has been demonstrated since
both systemic and intrathecal injections of morphine,
specific (MK-801) and nonspecific NMDA-receptor
antagonists (DM) could cause a significant reduction of
hyperalgesia [18-23]. Moreover, injury-induced hyperal-
gesia, morphine tolerance, and changes in NR1 mRNA
produced by chronic morphine were found to be pre-
vented by the blockade of NMDA receptors in the
spinal cord dorsal horn [24-26]. Therefore, the spinal
NMDA-receptors were regarded as a functionally
important pronociceptive system which was also
correlated with hyperalgesia [27]. Although the detailed
mechanism of maternal DM to suppress NMDA-recep-
tor expression was unknown, our results provide some
possible biochemical evidence in connection with our
behavioral findings. Nevertheless, the increase of the
expression of NMDA receptor NR1 and NR2B subunits
should not be regarded as the sole reason for the higher
vulnerability to inflammatory thermal hyperalgesia in
prenatal morphine-exposed offspring. Many other bio-
chemical and physical changes could be also involved in
the generation of this higher vulnerability. For example,
the endogenous opioid peptides and opioid receptors
could be changed for their quantities or sensitivities by
prenatal morphine exposure. Certainly, the opioid sys-
tem may contribute to the higher vulnerability to hyper-
algesia. This requires further investigations on the
possible change of the opioi ds y s t e m .S of a r ,w ew e r e
only able to conclude that the quantitative change of
the NMDA receptor subunits may play a role.
Regarding to the pharmacological target of DM to
reduce the adverse effects of prenatal morphine, many
behavioral studies revealed that the NMDA receptor
antagonism of DM is important for its action to potenti-
ate the antinociceptive effect of morphine in rats [28,29].
Although a recent clinical report indicated that Morphi-
Dex (morphine sulfate/dextromethorphan hydrobromide
combination) failed to enhance opioid analgesia or
reduce tolerance [30], the possible contribution of
NMDA receptor blockade by DM could be still of
importance in its action to regulate pain. Depending on
the dose and the species, NMDA receptor antagonists
showed various effects to attenuate pain/nociception in
different animal models [31,32]. Therefore, DM may
possibly act through the blockade of NMDA receptors
to affect morphine-induced higher vulnerability to
hyperalgesia in offspring from morphine-treated dams.
However, the relevant mechanisms of prenatal DM
remain to be tested.
Conclusions
In summary, the present study provides behavioral and
biochemical evidences in neonatal rats passively exposed
to morphine throughout embryo stages, which suggest
that they could be more susceptible to developing many
adverse effects, such as inflammatory hyperalgesia. Ther-
apeutically, DM could reverse this adverse effect caused
by prenatal morphine. The current results also implied
the possible biological change in the CNS of offspring
from morphine-addicted mother in humans. Moreover,
the therapeutic potential of DM was further highlighted;
especially our recent report also indicated the ability of
DM to reduce morphine-induced hyperprolactinemia in
female rats at different reproductive stages [33].
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